Clinical & Experimental Immunology (CEI) is an international, authoritative, and timely journal publishing high-quality and impactful papers in the field of translational immunology. In the past year, we have updated our vision and scope and created new sections around key subject areas.
We aim to better serve the community by making sure our scope and editorial team reflect the research interests of our audience.
Our dedicated Section Editors are experts in their field and will be able to make decisions based on what will be of interest to their specialist community. As reflected by the breadth in expertise of our members and the wide variety of Affinity Groups within the Society, we know that our members appreciate access to subject-specific networks and up-to-date research relevant to them.
CEI ’s updated aims and scope reflect the increasing opportunities to study the immunological basis of human disease, driven by both technological and clinical advances. The journal now has a stronger emphasis on translational immunology studies that include a mechanistic component. We also welcome studies that inform clinical practice. Leonie Taams, CEI Editor-in-Chief
The journal has moved towards dedicated Section Editors, and each will have a supporting editorial board in the following areas: autoimmunity, immunemediated inflammatory diseases, cancer immunity, infectious diseases and vaccines, neuroimmunology, and allergy & respiratory diseases. Translational immunology articles that fall outside these areas will be evaluated by the Editor-in-Chief and our general editorial board. In this way, all articles will receive expert evaluation in a timely fashion.
If you are interested in finding out more about the sections or wish to submit to the journal, please visit our website.
The revenue derived from our journals provides major financial support for all the BSI’s activities so, by submitting your work, you’re supporting your Society.
The autoimmunity section is interested in articles that provide mechanistic insights into the establishment and maintenance of autoimmune responses and the molecular basis for the different molecular and clinical correlates of autoimmunity. The articles in this section cover a variety of rheumatological and immunological diseases, including diabetes, rheumatoid arthritis, Hashimoto’s thyroiditis, systemic lupus erythematosus and many more.
The autoimmunity section is led by Angelo Manfredi of Università Vita-Salute San Raffaele, Milan.
Example article: de Bont et al . 2020 Neutrophil proteases degrade autoepitopes of NET-associated proteins Clinical & Experimental Immunology 199 1–8
We welcome articles reporting on translational studies in animal models or in vitro human model systems with relevance for innovative immunotherapy strategies, as well as articles reporting on immune profiling of clinical samples and immune monitoring of clinical trials. Articles should provide novel mechanistic insights into the molecular and cellular processes governing natural tumour immunity, immune escape, or therapy efficacy. Emphasis should be on clinical or near-clinical applications for either solid tumours or haematological malignancies.
The cancer immunology section is led by Tanja de Gruijl, of VUmc, Amsterdam.
Example article: Lu et al . 2019 TNFderived peptides inhibit tumour growth and metastasis through cytolytic effects on tumour lymphatics Clinical & Experimental Immunology 198 198–211
Immune-mediated Inflammatory Diseases
This section welcomes high-quality, primary research articles that report on the mechanistic investigation of inflammation in humans. Studies can encompass a wide range of pathologies, transplant rejection or sterile inflammation. While the main focus should be on the immunological basis of inflammation, papers that additionally describe genetic, metabolic or neurogenic aspects of inflammation, are welcomed.
The immune-mediated inflammatory diseases section is led by Leonie Taams of King’s College London.
Example article: Steen-Louws et al . 2019 IL4-10 fusion protein: a novel immunoregulatory drug combining activities of interleukin 4 and interleukin 10 Clinical & Experimental Immunology 195 1–9
Infectious Diseases and Vaccines
In this section, we welcome articles focusing on both established as well as emerging infectious diseases, their treatment, and the development of prophylactic and therapeutic vaccines. We are especially interested in these topics as they apply to resource limited settings. Vaccine articles should not simply be descriptions of the production or formulation of a vaccine but should include a clinical or pre-clinical component that attests to the vaccine’s efficacy or immunogenicity. We are also interested in all aspects of the microbiome and its interaction with and influence on the immune system.
The infectious diseases and vaccines section is led by Xiao-Ning Xu (Imperial College London) and Danny Douek (National Institute of Allergy and Infectious Diseases/National Institutes of Health/ DHHS, USA).
Example article: Zhong et al . 2019 The impact of timing of maternal influenza immunization on infant antibody levels at birth Clinical & Experimental Immunology 195 139–152
Although neuroimmunologists originally focused on the classical neuroinflammatory disorders including multiple sclerosis and infections of the nervous systems, the immune response also plays a major role in many other diseases including genetic white matter disorders, epilepsy, neurodegenerative diseases, neuropsychiatric disorders, diseases of the peripheral nervous system and neuro-oncology. This section welcomes research papers on technological advances, animal and human studies, and outcomes from clinical trials regarding the contribution of the immune system to these diseases, as well as its role in brain development, ageing, and regeneration and repair.
The neuroimmunology section is led by Sandra Amor, of VUmc, Amsterdam.
Example article: Xue et al . 2019 Transcriptomes in rat sciatic nerves at different stages of experimental autoimmune neuritis determined by RNA sequencing Clinical & Experimental Immunology 198 184–197
Allergy and respiratory disease
This section is particularly interested in translational or clinical studies that report on the immunological basis of allergies as well as studies that provide immunological insight into the development, treatment or diagnosis of respiratory disease. Articles focusing on technologies or models that advance the immunological understanding of allergy or respiratory disease are also welcome.
Example article: Arakawa et al. 2019 Secretory immunoglobulin A induces human lung fibroblasts to produce inflammatory cytokines and undergo activation Clinical & Experimental Immunology 195 287–301.
Find out more
BSI Journals Manager email@example.com